Non-invasive tests for fibrotic MASH for reducing screen failure in therapeutic trials

Drug development in metabolic dysfunction-associated steatohepatitis (MASH) is hampered by a high screen failure rate, one of the main reasons being the absence of MASH and significant fibrosis (fibrotic MASH) on the baseline liver biopsy, a key inclusion criterion in MASH therapeutic trials. Non-invasive tests represent an attractive opportunity to better select candidates for these trials, but most of them have been developed for advanced fibrosis and the new tests designed for the diagnosis of fibrotic MASH remain poorly validated. In this work, we demonstrate that the tests specifically designed for fibrotic MASH are more accurate for this diagnostic target than the tests currently recommended and initially developed for advanced fibrosis. We propose sequential combinations that will facilitate the identification of patients with fibrotic MASH in need of treatment, and their inclusion in MASH therapeutic trials.

Authors

Institutions

Publication Details

Journal
JHEP Reports
Published
2025-02-04
DOI
https://doi.org/10.1016/j.jhepr.2025.101351
Citations
6
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
8.13
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Non-invasive tests for fibrotic MASH for reducing screen failure in therapeutic trials

Charlotte E. Costentin, Ming‐Hua Zheng, Marine Roux, C Moreau et al.
6 citations
JHEP Reports
Liver Disease Diagnosis and Treatment
8.13
article

Non-invasive tests for fibrotic MASH for reducing screen failure in therapeutic trials

Charlotte E. Costentin, Ming‐Hua Zheng, Marine Roux, C Moreau, Adèle Delamarre, Thomas Mouillot, Jérôme Boursier, Sven Francque, Luisa Vonghia, Jeanne Fichez
article en
6 citations

Abstract

Drug development in metabolic dysfunction-associated steatohepatitis (MASH) is hampered by a high screen failure rate, one of the main reasons being the absence of MASH and significant fibrosis (fibrotic MASH) on the baseline liver biopsy, a key inclusion criterion in MASH therapeutic trials. Non-invasive tests represent an attractive opportunity to better select candidates for these trials, but most of them have been developed for advanced fibrosis and the new tests designed for the diagnosis of fibrotic MASH remain poorly validated. In this work, we demonstrate that the tests specifically designed for fibrotic MASH are more accurate for this diagnostic target than the tests currently recommended and initially developed for advanced fibrosis. We propose sequential combinations that will facilitate the identification of patients with fibrotic MASH in need of treatment, and their inclusion in MASH therapeutic trials.

JHEP ReportsVol. 7(4)
Centre National de la Recherche Scientifique (FR), University of Antwerp (BE), Inserm (FR), Wenzhou Medical University (CN), First Affiliated Hospital of Wenzhou Medical University (CN), Antwerp University Hospital (BE), Hôpital Cardiologique du Haut-Lévêque (FR), Maison des Sciences sociales et des Humanités de Dijon (FR), Université d'Angers (FR), Université Grenoble Alpes (FR)
Openalex Percentile: Top 3%
Liver Disease Diagnosis and Treatment
8.13
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.